Influence of increasing intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on vascular function and risk factors for cardiovascular disease

King's College London (UK)0 个研究点目标入组 360 人开始时间: 2008年12月17日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. A reported history of angina, myocardial infarction or stroke
•2. Clinical history of cancer (excluding basal cell carcinoma) in the past five years
•3. Uncontrolled type 2 diabetes mellitus (fasting plasma glucose greater than 7 mmol/L)
•4. Type 1 diabetes mellitus
•5. Chronic renal, liver or inflammatory bowel disease
•6. Current cigarette smoker
•7. History of substance abuse or alcoholism (previous weekly alcohol intake greater than 60 units/men or 50 units/women)
•8. Current self-reported weekly alcohol intake not exceeding 21 units for women and 28 for men
•9. Currently pregnant, planning pregnancy or having had a baby in the last 12 months (there are no hazards from the EPA or DHA with regard to pregnancy outcome)
•10. Allergy or intolerance to any component of study capsules
•11. Unwilling to follow the protocol and/or give informed consent
•12. Unwilling to refrain from use of dietary supplements including other sources of fish oil (e.g. cod liver oil)
•13. Unwilling to restrict consumption of oily fish
•14. Weight change of greater than 3 kg in preceding 2 months
•15. Body mass index less than 20 and greater than 35 kg/m^2
•16. Subjects with an overall risk of cardiovascular disease over the next ten years of greater than 20% who have untreated high blood pressure or raised cholesterol (subjects who are on stable medication for blood pressure or serum cholesterol [statins] will be included)

发起方

King's College London (UK)